Quarterly report [Sections 13 or 15(d)]

Discontinued Operations - Schedule of Reconciliation of Discontinued Operations (Details)

v3.25.1
Discontinued Operations - Schedule of Reconciliation of Discontinued Operations (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Operating expenses:    
Income (loss) from discontinued operations $ 8,644 $ (741)
Pharmaloz | Discontinued Operations, Disposed of by Sale    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Revenues, net 0 1,278
Cost of revenues 0 1,651
Gross loss 0 (373)
Operating expenses:    
General and administration 102 294
Research and development 0 0
Total operating expenses 102 294
Loss from operations (102) (667)
Interest expense 0 (74)
Income (loss) from discontinued operations $ (102) $ (741)